Ultima Genomics, a Newark, Ca.-based genomics company, emerged from stealth mode with approximately $600m in funding.
Backers included General Atlantic, Andreessen Horowitz, D1 Capital, Khosla Ventures, Lightspeed, Marius Nacht, aMoon, Playground Global, and Founders Fund.
Led by Gilad Almogy, founder and Chief Executive Officer, and Doron Lipson, Chief Scientific Officer, Ultima provides a new high-throughput, low-cost sequencing platform that leverages a new architecture to scale beyond conventional sequencing technologies and lower the cost of genomic information.
Biology’s complexity and dynamic nature has created a virtually unlimited need for genomic information. Currently, routine adoption of sequencing for research and diagnosis is severely constrained by cost. Over the last five years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches, including completely different approaches to flow cell engineering, sequencing chemistry, and machine learning.
FinSMEs
01/06/2022